{
    "clinical_study": {
        "@rank": "120883", 
        "arm_group": {
            "arm_group_label": "Kuvan\u00ae", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, non-comparative, Phase 3 study to evaluate the degree, frequency of\n      response and safety of Kuvan\u00ae in subjects aged 4 to 18 years who have phenylketonuria  with\n      elevated blood phenylalanine level of greater than or equal to 450 micromole per liter."
        }, 
        "brief_title": "Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan\u00ae in Patients With Phenylketonuria", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Phenylketonuria", 
        "condition_browse": {
            "mesh_term": "Phenylketonurias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent (for children under 18 years old\n             the parent(s)/guardians give informed consent, subjects 14-17 years old give\n             additionally their own written informed consent)\n\n          -  Age of 4 - 18 years, inclusive\n\n          -  Confirmed clinical and biochemical Hyperphenylalaninemia due to phenylketonuria\n             documented by past medical history with at least 2 blood Phenylalanine  level greater\n             than or equal to 400 micromole per liter obtained in 2 separate occasions\n\n          -  Blood phenylalanine level at screening greater than or equal to 450 micromole per\n             liter (mean of two measurements)\n\n          -  For women of childbearing potential, a negative urine pregnancy test is required at\n             screening and willingness to use a highly effective method of contraception is\n             required while participating in the study\n\n          -  Subject and/or the parent/guardian willing and able to comply with study procedures\n\n          -  Subject and/or the parent/guardian willing to continue current diet unchanged during\n             the 8 days response test and to adapt the diet according to Phenylalanine therapeutic\n             target range during the 6 week treatment period\n\n        Exclusion Criteria:\n\n          -  Subject already assessed for responsiveness to sapropterin dihydrochloride or other\n             tetrahydrobiopterin (BH4)\n\n          -  Used any investigational agent other than Kuvan\u00ae within 30 days of screening, or\n             required any investigational agent or vaccine prior to completion of all scheduled\n             study assessments\n\n          -  Pregnant or breastfeeding, or considering pregnancy\n\n          -  Concurrent disease or conditions that would interfere with study participation or\n             safety (for example, seizure disorder, asthma or other condition requiring oral or\n             parenteral corticosteroid administration, insulin-dependent diabetes, or organ\n             transplantation recipient)\n\n          -  Concurrent use of required concomitant treatment with any drug known to inhibit\n             folate synthesis (e.g. methotrexate), levodopa, phosphodiesterase type-5 (PDE-5)\n             inhibitors (such as, sildenafil, vardenafil or tadalafil), medications that are known\n             to affect nitric oxide synthesis metabolism or action\n\n          -  Any conditions, that, in the view of the Principal Investigator renders the subject\n             at high risk for failure to comply with treatment or to complete the study\n\n          -  Clinical diagnosis of primary BH4 deficiency\n\n          -  Known hypersensitivity to Kuvan\u00ae or its excipients or to other approved or\n             non-approved formulation of tetrabiopterin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732471", 
            "org_study_id": "EMR 700773_510"
        }, 
        "intervention": {
            "arm_group_label": "Kuvan\u00ae", 
            "description": "Kuvan\u00ae oral soluble tablet will be administered once daily in the morning, as 20 milligram per kilogram of the subject's body mass. The therapy duration will depend on the response to treatment - either up to 8 days, (if there will be no response), or up to 7 weeks (if there will be response).", 
            "intervention_name": "Kuvan\u00ae", 
            "intervention_type": "Drug", 
            "other_name": [
                "Sapropterin dihydrochloride", 
                "6R-BH4 tetrahydrobiopterin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "EMR 700733_510, Genetic disorder, Phenylketonuria, phenylalanine, Kuvan, sapropterin dihydrochloride", 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact Merck KGaA Communication Center located in"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan\u00ae (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Russia: Ethics Council at the Ministry of Health of the Russian Federation", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Russia: Local Ethics Committees", 
                "Ukraine: Local Ethics Committee", 
                "Ukraine: Ministry of Health of Ukraine", 
                "Ukraine: State Expert Center of Ministry of Ukraine"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response to Kuvan\u00ae after 8-day treatment defined as a reduction in blood Phenylalanine levels of greater than or equal to 30 percent as compared to beginning of the test prior to dosing", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732471"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage change from baseline in blood phenylalanine level after 8-day Kuvan\u00ae therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 8"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Week 11 (+/- 1 Week)"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}